Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

This article was originally published in PharmAsia News

Executive Summary

Dr. Reddy's Laboratories reported revenues exceeding $1 billion for the first time during the first nine months of fiscal 2007 (ended Dec. 31)

You may also be interested in...



Par Launches Generic Zofran ODT Following FDA Clearance

The agency also clears Dr. Reddy’s immediate-release ondansetron formulation which the Indian firm said it will launch shortly.

Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec

Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.

Generic Giant: Dr. Reddy’s Acquires Betapharm Group

With the $576 mil. acquisition of Betapharm, Dr. Reddy’s will expand its presence in Europe.

Related Content

UsernamePublicRestriction

Register

SC065646

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel